Pulmatrix presents iCALM clinical study results
The study concluded that iCALM is a novel inhaled therapeutic with a previously unexplored mechanism of action that can lead to better control of symptoms and lung function
Teva Pharmaceuticals International and Polpharma Biologics have signed a global licensing agreement for a proposed biosimilar to Ocrevus (ocrelizumab) to treat multiple sclerosis (MS).